Three members of the Dunbar Pharma team have been shortlisted for a combined four nominations at the Cannabis Industry Awards 2026, highlighting their dedication and contributions to scientific excellence, innovation and environmental sustainability within the cannabis industry.
The Cannabis Industry Awards celebrate individuals whose dedication, expertise and achievements are helping to shape the future of the UK’s cannabis sector. This year’s awards recognise excellence across eight categories, highlighting contributions spanning scientific research, leadership, patient support and sustainability.
Three Dunbar Pharma employees have been shortlisted across two award categories:
-
- James Igoe, Head of Quality Control – Contribution to Science Award
- Rosarie Byrne, Validation Manager – Contribution to Science Award and The Green Award
- Lauryn Blair, Technical & Digital Innovations Lead – The Green Award
Recognisising Excellence Across the Dunbar Pharma Team
The four nominations recognise the individual achievements of three Dunbar Pharma employees across two award categories: the Contribution to Science Award and The Green Award.
James Igoe – Contribution to Science Award
James Igoe, Head of Quality Control, has been shortlisted for the Contribution to Science Award, presented by ECS Pharma. The award recognises individuals who have advanced the scientific understanding of cannabis through research, innovation and evidence-based practice. Reflecting on the recognition, James commented:
“I’m absolutely delighted to be nominated for the Contribution to Science award at this year’s Cannabis Industry Awards. This recognition is a testament to the hard work and dedication of our entire QC team at Dunbar Pharma—I’m so proud to work alongside such a talented group committed to pharma excellence.”
Lauryn Blair – The Green Award
Lauryn Blair, Technical Specialist, has been shortlisted for The Green Award, recognising contributions to innovation and environmental sustainability within the sector. Expressing her appreciation for the recognition, Lauryn said:
“I’m incredibly grateful to be recognised alongside so many inspiring individuals and organisations contributing to the growth and development of the cannabis industry. A huge thank you to everyone at Dunbar Pharma for the opportunities, support and encouragement to innovate and make a meaningful contribution to the industry. I’m very fortunate to work alongside such a dedicated and talented team.”
Rosarie Byrne – Contribution to Science Award & The Green Award
Rosarie Byrne, Validation Manager, has received two nominations at this year’s awards, having been shortlisted for both the Contribution to Science Award and The Green Award. Her nominations span two distinct areas of recognition, highlighting the breadth of her contributions to scientific excellence and environmental sustainability within the cannabis industry. Speaking about her two nominations, Rosarie shared:
“Absolutely delighted to be shortlisted for two Cannabis Industry Council Awards 2026 Contribution to Science and The Green Award! It’s incredibly rewarding to see the team’s hard work, dedication and innovation at Dunbar Pharma translate into reliable, consistent pharmaceutical products, and even more so to see those efforts recognised by others in the industry!”
Celebrating the People Behind Dunbar Pharma
These four nominations reflect the expertise, dedication and collaborative spirit of the Dunbar Pharma team. As an Irish EU GMP-certified manufacturer of plant-derived cannabinoid active pharmaceutical ingredients, Dunbar Pharma is committed to advancing pharmaceutical quality, scientific innovation and responsible manufacturing practices.
The recognition of three team members across two distinct award categories highlights the breadth of talent within the company and the important role individuals play in supporting its continued development.
The winners will be announced at the Cannabis Industry Awards ceremony on Wednesday, 11 November 2026, at the Honourable Artillery Company in London.
We are incredibly proud of James, Lauryn and Rosarie for their achievements and wish them the best of luck at the upcoming awards.
Congratulations to all nominees!
Further Reading
Media Contact
For further information, please contact:
Nicole Farah
Americana Communications Ltd.
pr@dunbarpharma.ie
www.americanapr.com
About Dunbar Pharma
Dunbar Pharmaceuticals (Mercury Rising Ltd.) is a privately owned Irish pharmaceutical manufacturer and Ireland’s first EU GMP manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs). Based in Athlone, Ireland, the company manufactures difficult-to-make, pharmaceutical-grade APIs, including plant-derived dronabinol, to recognised pharmacopoeia standards for regulated pharmaceutical markets, including Germany and the UK.
Built from the ground up as a pharmaceutical manufacturer on Ireland’s world-class pharma platform, Dunbar Pharma operates under the oversight of the Health Products Regulatory Authority (HPRA), with validated processes and full batch traceability supporting dependable supply to licensed partners across Europe.
Dunbar Pharma was founded on a simple observation: medical use of cannabinoids was growing worldwide, but the pharmaceutical infrastructure behind it had not kept pace. The company is closing that gap, building Europe’s pharmaceutical infrastructure for plant-derived cannabinoid medicines by combining EU GMP manufacturing, pharmaceutical quality standards and reliable supply for healthcare partners and patients. The company has been recognised for its growth and innovation, including Emerging Company of the Year at the BioPharmaChem Impact Awards 2026, Product & Manufacturing Start-Up of the Year at the National Start-Up Awards 2025, and the Ambition & Growth Award at the Local Enterprise Office Awards 2026. Keep up to date on activity from Dunbar Pharma on LinkedIn.
Notes to Editor
Dunbar Pharmaceuticals (Mercury Rising Ltd.) is an Irish GMP manufacturer based in Athlone, Ireland. GMP Certificate: 35486/ASR13213/000001; ASR Certificate: ASR13213/000001 — verifiable on the EudraGMDP public register.
Dronabinol is the INN (international non-proprietary name) for delta-9-THC in purified pharmaceutical form, prescribed internationally for decades in regulated prescription medicines for specific indications.
Dunbar’s dronabinol is manufactured exclusively for pharmaceutical use, not consumer or wellness products.